https://hdl.handle.net/20.500.11811/825 2026-04-07T16:31:08Z https://hdl.handle.net/20.500.11811/9437 Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [²²³Ra]RaCl₂ therapy Sraieb, Miriam; Hirmas, Nader; Conrad, Rupert; Marinova, Milka; Essler, Markus; Herrmann, Ken; Ahmadzadehfar, Hojjat [²²³Ra]RaCl₂ dichloride treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with improved overall survival (OS) and a delay in the time to the first symptomatic skeletal-related event. The aim of this study was to evaluate the quality of life (QoL) of patients with mCRPC receiving [²²³Ra]RaCl₂ treatment using the European Organization for Research and Treatment of Cancer (EORTC) validated questionnaire form. <br /> Thirty patients with mCRPC were included in this study. The patients were administered the EORTC QLQ-C30 (version 3.0) questionnaire at 5 time points: before [²²³Ra]RaCl₂ treatment, after the first cycle, after the third cycle, after the fifth cycle, and at the end of the treatment. <br /> Median age at diagnosis was 65.2 years (range, 49.1–75.5). There was a significant 25% drop in the median alkaline phosphatase levels: 101U/L (range, 58–594) vs. 75 U/L (39–649) before and during treatment, respectively (P=.003). The median dose of [²²³Ra]RaCl₂ for all patients was 4.1 MBq (range, 3.35–6.55), and the majority of patients received 5 treatment cycles (range 3–6). Seventeen patients were alive at the end of treatment (56.7%). The median OS was 26 months (range, 19.8–32.2). All of the patients filled out the questionnaires at the first 3 time points; the fourth survey included 28 patients, and only 23 patients completed the fifth questionnaire. Compared to the baseline, only the scale “role functioning” showed a temporary worsening after the first therapy cycle (P=.03). In subsequent cycles, its mean value rose to initial levels. All other functional and symptom scales, as well as global health status, remained constant over all 5 time points and showed no significant changes (P>.05). <br /> [²²³Ra]RaCl₂ therapy does not adversely impair the health-related QoL of patients with mCRPC and bone metastasis. Only patients’ role functioning worsened temporarily after the first therapy cycle but stabilized in subsequent treatment cycles. 2020-08-19T00:00:00Z